Navigation Links
ExonHit Appoints a New Management Board
Date:3/31/2008

ng industry. ExonHit Therapeutics has it all. We all are very excited about working together to exploit these assets. This is the legacy the founders left us and it is our duty to convert them into successful products for the benefit of the patients and of our shareholders. ExonHit Therapeutics has continued to make strong progress since the beginning of 2008 with the registered positive effect of our lead compound (EHT0202) in the clinical Phase 1 "scopolamine" trial and recruitments of patients both in our diagnostics and therapeutics studies going according to plan. I am convinced ExonHit Therapeutics has all the assets and talents to bring to the market innovation patients need."

About ExonHit Therapeutics

http://www.exonhit.com

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer's disease or atherosclerosis.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-cli
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ExonHit Therapeutics - 2007 Financial Results
2. ExonHit Builds A New Organisation
3. ExonHit and bioMerieux Amend Their Strategic Partnership
4. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
5. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
6. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
7. Pharmasset Appoints Herbert J. Conrad as a Director
8. MacroChem Appoints David P. Luci as New CFO
9. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
10. RainDance Appoints Becker Chief Commercial Officer
11. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Follow us on LinkedIn –Cholesterol ... cholesterol carrier or lipoprotein in the blood. Such tests ... in the body, especially along the walls of blood ... other cardiovascular disorders. Cardiovascular Diseases (CVD) is the leading ... on a regular basis, to assess an individual’s risk ...
(Date:9/30/2014)... 2014 CORD:USE Cord Blood Bank – ... has entered into an Equity and Exclusive Services Agreement ... series of patented technologies for the isolation of human ... Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
(Date:9/30/2014)...  KemPharm, Inc., a clinical-stage specialty pharmaceutical company ... new molecular entity (NME) prodrugs, announced today that ... issued U.S. Patent No. 8,816,083 to KemPharm for ... Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydromorphone, ... The patent, which extends through 2032, provides ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... — Just in case anyone doubts that the Wisconsin Alumni ... defend its stem cell patent, Andy Cohn would like to ... manager for WARF, said the foundation, armed with a $1.5 ... to its controversial stem cell patent. , ,In the wake ...
... had the opportunity to watch lots of little companies become ... a company is no less awkward than a child's trip ... big without really growing up. , ,Fortunately, that isn't ... the social media market. Over the last year, the company ...
... Joint Legislative Audit Committee voted unanimously to authorize an ... agencies. , ,The 6-0 vote came after several hours ... personnel confirmed the state has lost millions of dollars ... several agencies have been plagued by varying problems, including ...
Cached Biology Technology:WARF says it's ready for a legal challenge on stem cells 2WARF says it's ready for a legal challenge on stem cells 3WARF says it's ready for a legal challenge on stem cells 4Six Apart grows up 2Six Apart grows up 3Audit of multi-million dollar state IT spending will proceed 2
(Date:9/30/2014)... most comprehensive assessment conducted by the Ocean Health ... of 100 in overall health. In addition, for ... and the 15 ocean regions beyond national jurisdiction ... a healthy climate, safeguarding biodiversity and providing sustainable ... of the index, a partnership led by scientists ...
(Date:9/30/2014)... led by Clemson University associate professor Brian Powell, ... the U.S. Department of Energy,s Experimental Program to ... impact on South Carolina in the advancement of ... "Understanding the scientific and engineering needs for safely ... technologies is imperative if South Carolina is to ...
(Date:9/30/2014)... -- Pollution in urban and farm runoff in Hawaii ... study finds. , The study, published Tuesday in ... nitrogen in the runoff ends up in algae that ... the animals, eyes, flippers and internal organs. , Scientists ... National Oceanic and Atmospheric Administration (NOAA) conducted the study ...
Breaking Biology News(10 mins):Rating the planet's oceans 2Rating the planet's oceans 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... evidence a chemical referred to as hexavalent chromium, or ... is consumed in drinking water. The two-year study ... animals given hexavalent chromium developed malignant tumors. , ... cancer in humans in certain occupational settings as a ...
... has examined the mechanisms behind latent cell memory, which ... suddenly to appear. Special yeast cells for example, can ... hermaphrodite. , Researchers from the Niels Bohr Institute ... and computer simulations to examine fundamental mechanisms of cell ...
... international journal, the British Journal of Obstetrics and Gynaecology, ... increases in clinical reasons for caesareans such as complications ... to societal factors. , The research project looked at ... (more than 430,000 births) and analysed the ...
Cached Biology News:Hexavalent chromium in drinking water causes cancer in lab animals 2Latent memory of cells comes to life 2Latent memory of cells comes to life 3Study shows dramatic increase in Caesarean sections 2
MOUSE ANTI BOVINE TROPONIN I...
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG...
Normal donkey serum collected from healthy normal donkeys....
This BioSolution package is excellent for doing fluorescence thermal melt experiments on nucleic acids, studies involving biomolecular interactions, protein folding experiments, and more!...
Biology Products: